The FDA could approve the first blood test that can detect multiple cancers, around the end of the year, setting the stage ...

Guardant Health, Inc., a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer screening is now covered for eligible UnitedHealth Group members 1, making it ...

Grail is awaiting an FDA ruling on a cancer screening test, but already more tests are finding their way into medical ...

One analyst called the insurer’s decision a “watershed moment” for liquid biopsy-based cancer screening and for the category ...

Forbes contributors publish independent expert analyses and insights. Jesse Pines is an expert in healthcare innovation and wellness. This voice experience is generated by AI. Learn more. This voice ...

ColoSense is designed for adults aged 45 to 85 years who are considered at average risk for colorectal cancer.

Some claim the new multi-cancer detection tests will “revolutionize” cancer screening. Others fear the “worried well” will succumb to slick marketing and subpar tests and overwhelm both primary care ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. This voice experience is generated by AI. Learn more. This voice ...

Apollo Cancer Centres has partnered with Zydus Lifesciences to introduce Guardant Health's Shield Multi-Cancer Detection ...

Zydus Lifesciences Ltd. has entered into an exclusive agreement with precision oncology company Guardant Health to introduce ...

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United ...

MoU signed with Apollo Hospitals to offer blood-based multi-cancer detection test for individuals aged 45 years and above ...